Vivanza Biosciences Ltd
Vivanza Biosciences Ltd (VIVANZA) last traded at ₹1.73, a market capitalisation of ₹6.92 crore, on a P/E of 15.0. Over the past 52 weeks the stock has ranged between ₹1.52 and ₹2.72. Vivanza Biosciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹9.29 crore and net profit of ₹0.15 crore. Vivanza Biosciences Ltd’s annual general meeting is scheduled for 11 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Vivanza Biosciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Vivanza Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹9.29 cr, up 3.9% from ₹8.94 cr a year earlier. Net profit was ₹0.15 cr, up 66.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 1.5 | 0.48 | 8.94 | 55.36 | 45.25 | 6.36 | 9.29 |
| Expenses | 2.89 | 1.37 | 1.44 | 8.79 | 54.75 | 45.04 | 6.59 | 9.36 |
| Operating profit | 0.11 | 0.13 | -0.96 | 0.15 | 0.61 | 0.21 | -0.23 | -0.07 |
| OPM % | 3.67% | 8.67% | -200.00% | 1.68% | 1.10% | 0.46% | -3.62% | -0.75% |
| Other income | 0 | 0.01 | 0.05 | 0.02 | 0.01 | 0.08 | 0.01 | 0.37 |
| Interest | 0.09 | 0.09 | 0.08 | 0.08 | 0.05 | 0.09 | 0.07 | 0.11 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Profit before tax | 0.02 | 0.05 | -0.99 | 0.09 | 0.57 | 0.2 | -0.3 | 0.18 |
| Tax % | 0.00% | 0.00% | 1.01% | 0.00% | 0.00% | 0.00% | 50.00% | 22.22% |
| Net profit | 0.02 | 0.04 | -1 | 0.09 | 0.56 | 0.2 | -0.45 | 0.15 |
| EPS (₹) | 0.00 | 0.01 | -0.25 | 0.02 | 0.14 | 0.05 | -0.11 | 0.04 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Vivanza Biosciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 10 | 10 | 18 | 28 | 7 | 116 | 116 |
| Operating profit | 0 | -0 | 1 | 1 | -0 | 1 | 1 |
| OPM % | 0.9% | -0.6% | 3.8% | 3.9% | -4.9% | 0.6% | 0.5% |
| Net profit | 0 | 0 | 1 | 1 | -1 | 0 | 0 |
| EPS (₹) | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 | 0.10 | 0.12 |
TTM is the trailing twelve months to the most recent quarter.
Vivanza Biosciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 64%
- 3 Years
- 87%
- TTM
- 735%
- 10 Years
- 24%
- 5 Years
- 37%
- 3 Years
- -13%
- TTM
- 154%
- 10 Years
- -13%
- 5 Years
- -31%
- 3 Years
- -45%
- 1 Year
- -13%
- 10 Years
- 2%
- 5 Years
- 6%
- 3 Years
- 2%
- Last Year
- 9%
Vivanza Biosciences Ltd shareholding pattern
Promoters held 20.02% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 39.86% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% |
| Public | 60.13% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% |
| No. of shareholders | 16,701 | 20,635 | 20,833 | 20,458 | 20,170 | 19,822 | 19,461 | 19,254 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Vivanza Biosciences Ltd’s AGM?
Vivanza Biosciences Ltd’s annual general meeting is scheduled for 11 Sept 2026.
- AGM44th Annual General Meeting to adopt financial statements, re-appoint director, and approve related party transactions and borrowing limits
See the full results calendar for every Indian company reporting in the next 30 days.
Vivanza Biosciences Ltd corporate filings
- Announcement Under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Vivanza Biosciences Limited has issued a formal notice for its 44th Annual General…
Read the full analysis - Annual Report for the Financial Year 2025-2026 of the Company.Otherslow impact
Cruxal's analysis: Vivanza Biosciences Ltd has filed its Annual Report for the financial year 2025-2026. The…
Read the full analysis - Notice of the 44th Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26AGM/EGMhigh impact
Cruxal's analysis: Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September…
Read the full analysis - The Board of Directors of the Company at its meeting held on Monday, August 17, 2026, at the Registered Office, inter alia, considered and approved: 1. Director's Report, Secretarial Audit ....Board Meetinglow impact
Cruxal's analysis: Vivanza Biosciences Limited has announced the scheduling of its 44th Annual General…
Read the full analysis - Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve 1) To consider and approve ....Board Meetinglow impact
Cruxal's analysis: Vivanza Biosciences Limited has issued an intimation for a Board Meeting scheduled on…
Read the full analysis - Pursuant to Regulation 32 of the SEBI(LODR) Regulation, 2015 Read with SEBI circular dated 24th December, 2019 regarding the submission of the statement of deviation or variation from the ....Company Updatelow impact
Cruxal's analysis: Vivanza Biosciences Ltd has formally declared that the Statement of Deviation or…
Read the full analysis - in the terms of Regulation 47 of the SEBI(LODR) Regulation, 2015 Please find the copy of the Newspaper in the English and vernacular Language of the State, wherein the Unaudited Standalone ....Company Updatelow impact
Cruxal's analysis: Vivanza Biosciences Limited has formally intimated the publication of its unaudited…
Read the full analysis - Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, along with year-to-date figures for the period from 1st April, 2026, to 30th ....Board Meetinghigh impact
Cruxal's analysis: Vivanza Biosciences Limited has released its unaudited financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Vivanza Biosciences Ltd
Cruxal reads every Vivanza Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.